Lipoprotein(a) and apolipoprotein(a) isoforms and proteinuria in patients with moderate renal failure

Kidney International

Volumn 56, Issue 3, 1999, Pages 1049-1057

  Sechi, Leonardo A ^a,b   Zingaro, Laura ^a   Catena, Cristiana ^a   Perin, Antonella ^a   De Marchi, Sergio ^a   Bartoli, Ettore ^a  

^a UNIVERSITY OF UDINE   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

Author keywords

Atherosclerotic disease; Cardiovascular disease; Hypertension; Lipids; Proteinuria

Indexed keywords

APOLIPOPROTEIN A; LIPOPROTEIN A;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CREATININE CLEARANCE; DISEASE ASSOCIATION; FEMALE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEINURIA; RISK FACTOR;

EID: 0032853297     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1999.00621.x     Document Type: Article

References (63)

1. 1. Kim KE, Swartz C: Cardiovascular complications of end stage renal disease, in Diseases of the Kidney, edited by Schrier RW, Gottschalk CW, Boston, Little Brown, 1988, pp 3093-3126
2. 2. Jensen T, Stender S, Deckert T: Abnormalities in plasma concentrations of lipoproteins and fibrinogen in type I (insulin-dependent) diabetic patients with increased urinary albumin excretion. Diabetologia 31:142-145, 1988
3. 3. Chan MK, Varghese Z, Moorhead JK: Lipid abnormalities in uremia, dialysis and transplantation. Kidney Int 19:625-637, 1981
4. 4. Goldberg AP, Harter HR, Patsch W: Racial differences in plasma high density lipoproteins in patients receiving hemodialysis. N Engl J Med 308:1245-1252, 1985
5. 5. Bostom AG, Gohh RY, Beaulieu AJ, Nadeau MR, Hume AL, Jaques PF, Selhub J, Rosenberg IH: Treatment of hyperhomocysteinemia in renal transplant recipients. Ann Intern Med 127:1089-1092, 1997
6. 6. Utermann G: The mysteries of lipoprotein(a). Science 246:904-910, 1989
7. 7. Berg K: A new serum type system in man: The Lp(a) system. Acta Pathol Microbiol Scand 59:369-382, 1963
8. 8. Brunner C, Kraft HG, Utermann G, Muller HJ: Cys (4057) of apolipoprotein(a) is essential for lipoprotein(a) assembly. Proc Natl Acad Sci USA 90:11643-11647, 1993
9. 9. Koschinsky ML, Cote GP, Gabel B, Van Der Hoek YY: Identification of the cysteine residue in apolipoprotein(a) that mediates extracellular coupling with apolipoprotein B-100. J Biol Chem 268:19819-19825, 1993
10. 10. Utermann G, Menzel HJ, Kraft HG, Duha HC, Kemmler HG, Seitz C: Lp(a) glycoprotein phenotypes: Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest 80:458-465, 1987
11. 11. Kraft HG, Kochl S, Menzel HJ, Sandholzer C, Utermann G: The apolipoprotein(a) gene: A transcribed hypervariable locus controlling plasma lipoprotein(a) concentrations. Hum Genet 90:220-230, 1992
12. 12. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH: Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 90:52-60, 1992
13. 13. Rader DJ, Hoeg JM, Brewer HB Jr: Quantitation of plasma apolipoproteins and the primary and secondary prevention of coronary artery disease. Ann Intern Med 120:1012-1025, 1994
14. 14. Kronenberg F, Steinmetz A, Kostner GM, Dieplinger H: Lipoprotein(a) in health and disease. Crit Rev Clin Lab Sci 33:495-543, 1996
15. 15. Jauhiainen M, Koskinen P, Ehnholm C: Lipoprotein(a) and coronary heart disease risk: A nested case-control study of the Helsinki Heart Study participants. Atherosclerosis 89:59-67, 1991
16. 16. Ridker PM, Hennekens CH, Stampfer MJ: A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA 270:2195-2199, 1993
17. 17. Scanu AM, Fless GM:. Lipoprotein(a): Heterogeneity and biological relevance. J Clin Invest 85:1709-1715, 1990
18. 18. Kronenberg F, Utermann G, Dieplinger H: Lipoprotein(a) in renal disease. Am J Kidney Dis 27:1-25, 1996
19. 19. Sechi LA, Zingaro L, De Carli S, Sechi G, Catena C, Falleti E, Dell'Anna E, Bartoli E: Increased serum lipoprotein(a) levels in patients with early renal failure. Ann Intern Med 129:457-461, 1998
20. 20. Haffner SM, Gruber KK, Aldrete G, Morales PA, Stern MP, Tuttle KR: Increased lipoprotein(a) concentrations in chronic renal failure. J Am Soc Nephrol 3:1156-1162, 1992
21. 21. Arnadottir M, Thysell H, Nilsson-Ehle P: Serum lipoprotein(a) concentration is increased in moderate renal failure. Nephron 72:712-713, 1996
22. 22. De Lima JJ, Maranhao RC, Latrilha M, Diament J, Romeo JE, Krieger EM, Pileggi F: Early elevation of lipoprotein(a) in chronic renal insufficiency. Renal Fail 19:145-154, 1997
23. 23. Monzani G, Bergesio F, Ciuti R, Ciciani AM, Martinelli F, Rosati A, Salvadori M: Lp(a) levels: Effects of progressive chronic renal failure and dietary manipulation. J Nephrol 10:41-45, 1997
24. 24. Dieplinger H, Lackner C, Kronenberg F, Sandholzer C, Lhotta K, Hoppichler F, Graf H, Konig P: Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a). J Clin Invest 91:397-401, 1993
25. 25. Bagdade JD, Porte D Jr, Bierman EL: Hypertriglyceridemia: A metabolic consequence of chronic renal failure. N Engl J Med 279:181-185, 1968
26. 26. Dieplinger H, Schoenfeld PY, Fielding CJ: Plasma cholesterol metabolism in end-stage renal disease. J Clin Invest 77:1071-1083, 1986
27. 27. Petrie JC, O'Brien ET, Littler WA, De Swiet M: Recommendations on blood pressure measurement. BMJ 293:611-615, 1986
28. 28. The Guidelines Subcommittee of the WHO/ISH Mild Hypertension Liaison Committee: 1993 Guidelines for the management of mild hypertension. Memorandum from a World Health Organization/International Society of Hypertension Meeting. Hypertension 22:392-403, 1993
29. 29. Sechi LA, Melis A, Tedde R: Insulin hypersecretion: A distinctive feature between essential and secondary hypertension. Metabolism 11:1261-1266, 1992
30. 30. Sechi LA, Kronenberg F, De Carli S, Falleti E, Zingaro L, Catena C, Utermann G, Bartoli E: Association of lipoprotein(a) levels and apolipoprotein(a) size polymorphism with target-organ damage in arterial hypertension. JAMA 277;1689-1695, 1997
31. 31. Friedewald WT, Levy RI, Friedrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative centrifuge. Clin Chem 18:499-502, 1972
32. 32. Irish GR, Barrantes DM, Ledue TB: Immunoturbidimetry of apolipoprotein B in human serum. Clin Chem 33:1267-1270, 1987
33. 33. Kraft HG, Lingenhel A, Bader G, Kostner GM, Utermann G: The relative electrophoretic mobility of apo(a) isoforms depends on the gel system: Proposal of a nomenclature for apo(a) phenotypes. Atherosclerosis 125:53-61, 1996
34. 34. Kronenberg F, Konig P, Neyer U, Auinger M, Pribasnig A, Lang U, Rettinger J, Pinter J, Utermann G, Dieplinger H: Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 6:110-120, 1995
35. 35. Sandholzer C, Saha N, Kark JD, Rees A, Jaross W, Dieplinger H, Hoppichler F, Boerwinkle E, Utermann G: Apo(a) isoforms predict risk for coronary artery disease: A study of six populations. Arterioscler Thromb 12:1214-1226, 1992
36. 36. Molgaard J, Klausen IC, Lassvik C, F/rgeman O, Gerdes LU, Olsson AG: Significant association between low-molecular-weight apolipoprotein(a) isoforms and intermittent claudication. Arterioscler Thromb 12:895-901, 1992
37. 37. Galle J, Bengen J, Schollmeyer P, Wanner C: Impairment of endothelium-dependent dilation in rabbit renal arteries by oxidized lipoprotein(a): Role of oxygen-derived radicals. Circulation 92:1582-1589, 1995
38. 38. Kostner KM, Clodi M, Bonlaj G, Watschinger B, Horl W, Derfler K, Huber K: Decreased urinary apolipoprotein(a) excretion in patients with impaired renal function. Eur J Clin Invest 28:447-452, 1998
39. 39. Austin MA, Sandholzer C, Selry JV, Newman B, Krauss RM, Utermann G: Lipoprotein(a) in woman twins: Heritability and relationship to apolipoprotein(a) phenotypes. Am J Hum Genet 51:829-840, 1992
40. 40. Jenner JL, Ordovas JM, Lamon-Fava S: Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels: The Framingham Offspring Study. Circulation 87:1135-1141, 1993
41. 41. Kraft HG, Menzel HJ, Hoppichler F, Vogel W, Utermann G: Changes of genetic apolipoprotein phenotypes caused by liver transplantation: Implications for apolipoprotein synthesis. J Clin Invest 83:137-142, 1989
42. 42. McLean JW, Tomlinson JE, Kuang W-J, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM: cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 300:132-137, 1987
43. 43. Hixson JE, Britten S, Manis G, Rainwater DL: Apolipoprotein(a) apo(a) glycoprotein isoforms result from size differences in apo(a) mRNA in baboons. J Biol Chem 264:6013-6016, 1989
44. 44. Krempler F, Kostner GM, Bolzano K, Sandhofer F: Turnover of lipoprotein(a) in man. J Clin Invest 65:1483-1490, 1980
45. 45. Rader DJ, Cain W, Ikewaki K, Talley G, Zech LA, Usher D, Brewer HB Jr: The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in lipoprotein(a) catabolism but to differences in production rate. J Clin Invest 93:2758-2763, 1994
46. 46. Rader DJ, Mann WA, Cain W, Kraft H-G, Usher D, Zech LA, Hoeg JM, Davignon J, Lupien P, Grossman M, Wilson JM, Brewer HB Jr: The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in human. J Clin Invest 95:1403-1408, 1995
47. 47. Slunga L, Johnson O, Dahlen GH: Changes in Lp(a) lipoprotein levels during the treatment of hypercholesterolemia with simvastatin. Eur J Clin Pharmacol 43:369-373, 1995
48. 48. Hofman SL, Eaton DL, Brown MS, McConathy WJ, Goldstein JL, Hammer RE: Overexpression of human LDL receptors leads to accelerated catabolism of Lp(a) lipoprotein in transgenic mice. J Clin Invest 85:1542-1547, 1990
49. 49. Floren CH, Albers JJ, Bierman EL: Uptake of Lp(a) lipoprotein by cultured fibroblasts. Biochem Biophys Res Commun 102:636-639, 1981
50. 50. Maartmann-Moe K, Berg K: Lp(a) lipoprotein enters cultured fibroblasts independently of the plasma membrane low density lipoprotein receptor. Clin Genet 20:352-362, 1981
51. 51. Harkes L, Jurgens G, Holasek A, Berkel TJC: In vivo studies on the binding sites for lipoprotein(a) on parenchymal and non-parenchymal rat liver cells. FEBS Lett 229:27-31, 1988
52. 52. Oida K, Takai H, Maeda H, Takahashi S, Shimada A, Suzuki J, Tamai T, Nakai T, Miyabo S: Apolipoprotein(a) is present in urine and its excretion is decreased in patients with renal failure. Clin Chem 38:2244-2248, 1992
53. 53. Zheng G, Bachinsky DR, Stramenkovic I, Strickland DK, Brown D, Andres G, McCluskey RT: Organ distribution in rats of two members of the low-density lipoprotein receptor gene family, gp 330 and LRP/alpha 2MR, and the associated protein (RAP). J Histochem Cytochem 42:531-542, 1994
54. 54. Marz W, Beckmann A, Scharnagl H, Siekmeier R, Mondorf U, Held I, Schneider W, Preissner KT, Curtiss LK, Gross W, Huttinger M: Heterogeneous lipoprotein(a) size isoforms differ by their interaction with the low density lipoprolein receptor and the low density lipoprotein receptor-related protein/alpha2-macroglobulin receptor. FEBS Lett 325:271-275, 1993
55. 55. Appel GB, Blum CB, Chien S, Kunis CL, Appel AS: The hyperlipidemia of nephrotic syndrome: Relation to plasma albumin concentration, oncotic pressure and viscosity. N Engl J Med 312:1544-1548, 1985
56. 56. Yang WS, Kim S, Min WK, Park S, Lee MS, Park JS: Atherogenic lipid profile and lipoprotein(a) in relation to serum albumin in hemodialysis patients. Nephrol Dial Transplant 10:1668-1671, 1995
57. 57. Querfeld U, Lang M, Friedrich JB, Kohl B, Fiehn W, Scharer K: Lipoprotein(a) serum levels and apolipoprotein(a) phenotypes in children with chronic renal disease. Pediatr Res 34:772-776, 1993
58. 58. Wanner C, Rader D, Bartens W, Kramer J, Brewer HB, Schollmeyer H, Wieland H: Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome. Ann Intern Med 119:263-269, 1993
59. 59. Stenvinkel P, Berglund L, Heimburger O, Petterson E, Alvestrand A: Lipoprotein(a) in nephrotic syndrome. Kidney Int 44: 1116-1123, 1993
60. 60. Gansevoort RT, Heeg JE, Dikkschei FD, De Zeeuw D, De Jong PE, Dullaart RPF: Symptomatic antiproteinuric treatment decreases serum lipoprotein(a) concentration in patients with glomerular proteinuria. Nephrol Dial Transplant 9:244-250, 1993
61. 61. Cressman MD, Heyka RJ, Paganini EP, O'Neil J, Sbikinski CI, Hoff HF: Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 86:475-482, 1992
62. 62. Kronenberg F, Kathrein H, Konig P, Neyer U, Sturm W, Lhotta K, Grochenig E, Utermann G, Dieplinger H: Apolipoprotein(a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease. Arterioscler Thromb 14:1405-1411, 1994
63. 63. Jungers P, Massy ZA, Nguyen Khoa T, Fumeron C, Labrunie M, Lacour B, Descamps-Latscha B, Man NK: Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients. Nephrol Dial Transplant 12:2597-2602, 1997